Los Angeles's major cancer centres including Cedars-Sinai and City of Hope manage substantial numbers of Chronic Myeloid Leukaemia (CML) patients on long-term Imatinib therapy. Imatib 400mg, the Indian generic of Gleevec, provides identical treatment at significantly reduced cost.
Imatib targets the BCR-ABL protein created by the Philadelphia chromosome — the genetic abnormality driving CML — transforming what was once a fatal leukaemia into a manageable chronic condition for most patients. It's also widely used for Gastrointestinal Stromal Tumours (GIST), targeting mutated KIT and PDGFRA receptors.
Generic Imatib from USFDA-inspected manufacturers offers the same efficacy as brand Gleevec at a fraction of the cost, critical for Los Angeles's significant uninsured CML and GIST patient population.
Imatib targets the BCR-ABL protein created by the Philadelphia chromosome — the genetic abnormality driving CML — transforming what was once a fatal leukaemia into a manageable chronic condition for most patients. It's also widely used for Gastrointestinal Stromal Tumours (GIST), targeting mutated KIT and PDGFRA receptors.
Generic Imatib from USFDA-inspected manufacturers offers the same efficacy as brand Gleevec at a fraction of the cost, critical for Los Angeles's significant uninsured CML and GIST patient population.
How will I know if Imatib is working for my CML?Your oncologist will monitor response through regular blood tests (complete blood count) and specialized molecular tests measuring BCR-ABL transcript levels in your blood, typically every 3 months initially. A good response shows steadily declining BCR-ABL levels, ideally reaching "complete molecular remission" — where the abnormal genetic marker becomes undetectable. This monitoring schedule, not just symptom improvement, is how treatment success is actually measured in CML.